IP Verse

Treatment Of Breast Cancer - EP2739153

The patent EP2739153 was granted to Medivation Prostate Therapeutics on Aug 22, 2018. The application was originally filed on Jul 27, 2012 under application number EP12846720A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2739153

MEDIVATION PROSTATE THERAPEUTICS
Application Number
EP12846720A
Filing Date
Jul 27, 2012
Status
Opposition Rejected
Jun 11, 2021
Publication Date
Aug 22, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMay 21, 2019ELKINGTON AND FIFE -

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2010172975
DESCRIPTIONUS2011003839
DESCRIPTIONUS4559157
DESCRIPTIONUS4608392
DESCRIPTIONUS4820508
DESCRIPTIONUS4938949
DESCRIPTIONUS4992478
DESCRIPTIONUS7709517
DESCRIPTIONWO2010099238
DESCRIPTIONWO2010118354
DESCRIPTIONWO2011044327
INTERNATIONAL-SEARCH-REPORTUS2007004753
INTERNATIONAL-SEARCH-REPORTUS2008139634
INTERNATIONAL-SEARCH-REPORTUS2009111864
INTERNATIONAL-SEARCH-REPORTUS2010172975
INTERNATIONAL-SEARCH-REPORTUS2010210665
INTERNATIONAL-SEARCH-REPORTUS2011003839
INTERNATIONAL-SEARCH-REPORTUS2011130296
INTERNATIONAL-SEARCH-REPORTUS2011152348
INTERNATIONAL-SEARCH-REPORTUS2012214864
INTERNATIONAL-SEARCH-REPORTWO2010099238
INTERNATIONAL-SEARCH-REPORTWO2010118354
INTERNATIONAL-SEARCH-REPORTWO2011044327
OPPOSITIONUS2010172975
SEARCHUS2010172975

Non-Patent Literature (NPL) Citations (23) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- COCHRANE et al., "The Role of Androgen Receptor in Postmenopausal Breast Cancer", Endocrine Reviews, (20110600), vol. 32, no. 3
OPPOSITION- FRANCESCA DE AMICIS et al., "Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells", NIH Public Access Author Manuscript, (20101201), vol. 121, no. 1, pages 1 - 18, XP055597759
OPPOSITION- TISHEEKA R GRAHAM et al., "Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells", NIH Public Access Author Manuscript, (20091118), vol. 123, no. 1, ISSN 1573-7217, pages 1 - 18, XP055597765
OPPOSITION- MIN NI et al., "Targeting Androgen Receptor in Estrogen Receptor- Negative Breast Cancer", C ANCER CELL , CELL PRESS, US, vol. 20, no. 1, ISSN 1535-6108, (20110527), pages 119 - 131, (20110608), XP028379886
OPPOSITION- JUNG et al., "Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)", NIH Public Access Author Manuscript, (20100408), vol. 53, no. 7, pages 1 - 59, XP055597768
OPPOSITION- JESSICA L L ROBINSON et al., "Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1", THE EMBO JOURNAL, (20110624), vol. 31, no. 6, ISSN 0261-4189, pages 1617 - 1617, XP055164145
OPPOSITION- RISBRIDGER et al., "Breast and prostate cancer: more similar than different", Nature Reviews, Cancer, (20100300), vol. 10, pages 205 - 212, XP055597870
OPPOSITION- FARMER et al., "Identification of molecular apocrine breast tumours by microarray analysis", Oncogene, (20050000), vol. 24, pages 4660 - 4671, XP002530214
OPPOSITION- A S DOANE et al., "An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen", ONCOGENE, (20060220), vol. 25, ISSN 0950-9232, pages 3994 - 4008, XP055164285
OPPOSITION- GUCALP et al., "Triple-negative breast cancer: Role of the androgen receptor", The Cancer Journal, (20100100), vol. 16, no. 1, pages 62 - 65, XP055597795
OPPOSITION- LEHMANN B D et al., "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (20110701), vol. 121, no. 7, ISSN 0021-9738, pages 2750 - 2767, XP002696927
OPPOSITION- SANTANA-DAVILA RAFAEL et al., "Treatment options for patients with triple-negative breast cancer", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, (20101027), vol. 3, no. 1, ISSN 1756-8722, page 42, XP021083367
OPPOSITION- NADERI et al., "Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer", Breast Cancer Research, (20110000), pages 1 - 16, XP021097591
OPPOSITION- DAWN R COCHRANE et al., "Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide", BREAST CANCER RESEARCH , CURRENT SCIENCE , LONDON, GB, (20140122), vol. 16, no. 1, ISSN 1465-5411, page R7, XP021177323
OPPOSITION- TRAN et al., "Development of a second-generation antiandrogen for treatment of advanced prostate cancer", NIH Public Author Manuscript, (20090508), vol. 324, no. 5928, pages 1 - 11, XP055597876
SEARCH- FRANCESCA DE AMICIS ET AL, "Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, (20090617), vol. 121, no. 1, ISSN 1573-7217, pages 1 - 11, XP019787451 [Y] 1-13 * abstract *
SEARCH- TISHEEKA R GRAHAM ET AL, "Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, (20091118), vol. 123, no. 1, ISSN 1573-7217, pages 139 - 147, XP019814417 [Y] 1-13 * abstract * * page 143, column r, line 4 - page 144, column r, paragraph 1 * * page 145; figure 5 *
SEARCH- MIN NI ET AL, "Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer", CANCER CELL, CELL PRESS, US, vol. 20, no. 1, doi:10.1016/J.CCR.2011.05.026, ISSN 1535-6108, (20110527), pages 119 - 131, (20110608), XP028379886 [Y] 1-13 * abstract * * page 128, column l, paragraph last - page 129, column l, paragraph 1 * * page 128; figure 8 *
SEARCH- JESSICA L L ROBINSON ET AL, "Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1", THE EMBO JOURNAL, (20110624), vol. 31, no. 6, doi:10.1038/emboj.2012.59, ISSN 0261-4189, pages 1617 - 1617, XP055164145 [Y] 1-13 * abstract * * page 3020; figure 1 * * page 3020, column r, line 8 - page 3021, column l, paragraph 1 *
SEARCH- A S DOANE ET AL, "An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen", ONCOGENE, (20060220), vol. 25, no. 28, doi:10.1038/sj.onc.1209415, ISSN 0950-9232, pages 3994 - 4008, XP055164285 [Y] 1-13 * abstract * * page 4001, column l, paragraph 2 - page 4002, column r, paragraph 2 *
SEARCH- LEHMANN B D ET AL, "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (20110701), vol. 121, no. 7, doi:10.1172/JCI45014, ISSN 0021-9738, pages 2750 - 2767, XP002696927 [Y] 1-13 * abstract * * page 2758; figure 5 * * page 2760; figure 7 * * page 2762, column l, paragraph 3 * * page 2762, column r, paragraph last - page 2761, column l, paragraph 2 * * page 2764, column l, paragraph last - column r, paragraph 1 *
SEARCH- SANTANA-DAVILA RAFAEL ET AL, "Treatment options for patients with triple-negative breast cancer", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, (20101027), vol. 3, no. 1, doi:10.1186/1756-8722-3-42, ISSN 1756-8722, page 42, XP021083367 [Y] 1-13 * abstract * * page 48, column r, paragraph 3 *
SEARCH- DAWN R COCHRANE ET AL, "Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, (20140122), vol. 16, no. 1, doi:10.1186/BCR3599, ISSN 1465-5411, page R7, XP021177323 [T] 1-13 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents